

1. Record Nr.	UNINA9910972032203321
Autore	Nikanorova Marina
Titolo	Orphan Drugs in Epilepsy
Pubbl/distr/stampa	Montrouge, : JOHN LIBBEY EUROTTEXT, 2014
ISBN	9782742012343 2742012346
Edizione	[1st ed.]
Descrizione fisica	1 online resource (90 p.)
Collana	Topics in Epilepsy ; ; v.4
Altri autori (Persone)	JohannessenS. I GentonPierre
Disciplina	616.853
Soggetti	Epilepsy -- Treatment Brain Diseases Central Nervous System Agents Drug Industry Industry Therapeutic Uses Central Nervous System Diseases Nervous System Diseases Technology, Industry, and Agriculture Pharmacologic Actions Chemical Actions and Uses Disease Anticonvulsants Epilepsy Orphan Drug Production
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di contenuto	""Orphan Drugs in Epilepsy""; ""Contents""; ""Foreword""; ""Bromides""; ""Adrenocorticotrophic hormone and corticosteroids""; ""Stiripentol""; ""Felbamate""; ""Rufinamide""
Sommario/riassunto	Over half of epilepsies start before the age of 20 years and nearly 25% of them are refractory. A tiny proportion of them are even labelled a rare illness (ie: one affecting less than 200,000 people in the United

States or less than 5 out of 10,000 people in the European Union). For these patients, two problems in their management arise: In children, seizures affect an immature brain and can impact its development. It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
